TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35364066

Group type: EXPERIMENTAL
Intervention: Standard triple therapy for H pylori eradication (n=817)
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Placebo (n=813)
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Standard triple therapy for H pylori eradication (n=625 with successful eradication)
Number of subjects: 1630

Group type: COMPARATOR
Intervention: Placebo (n=527 with persistent H pylori infection)
Number of subjects: 1630

Group type: EXPERIMENTAL
Intervention: Standard triple therapy for H pylori eradication (n=625)
Number of subjects: 1630
Study: 33953315

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 26
Study: 32187680

Group type: COMPARATOR
Intervention: Invasive placebo interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 0
Study: 37258943

Group type: EXPERIMENTAL
Intervention: 50 g whole almonds daily during the intervention period
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 43
Study: 33122092

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation Treatment (SDT) for 48 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (48 hours of normal sleep)
Number of subjects: 36
Study: 32502559

Group type: EXPERIMENTAL
Intervention: Earlier group (2-4 days postoperatively)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Later group (7 days postoperatively)
Number of subjects: 64
Study: 35477594

Group type: EXPERIMENTAL
Intervention: d-Amphetamine Transdermal System (d-ATS) 5 mg/9 h, with possible dose increase to 10 mg/9 h, 15 mg/9 h, and 20 mg/9 h during the study
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: d-Amphetamine Transdermal System (d-ATS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 33849830

Group type: EXPERIMENTAL
Intervention: Penalized AFT model including the main effect of covariate (Penalized, Eq_in)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Univariate AFT model excluding the main effect of covariate (Univariate, Eq_ex)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-stage adaptive design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responder subgroup
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Univariate AFT models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Penalized AFT models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adaptive design significance levels
Number of subjects: 0
Study: 35122668

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation at a dose of 400 IU/d (vD-400 group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (liquid product without vitamin D3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (vD-400 and placebo)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Participants with severe vitamin D deficiency
Number of subjects: 72
Study: 33966439

Group type: EXPERIMENTAL
Intervention: Embracing breast milk sucking (EBMS)
Number of subjects: 96
Study: 32866396

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 31
Study: 32347688

Group type: EXPERIMENTAL
Intervention: FineVision POD F
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RayOne Trifocal
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acrysof IQ PanOptix
Number of subjects: 45

Group type: COMPARATOR
Intervention: PODF
Number of subjects: 45

Group type: COMPARATOR
Intervention: RayOne
Number of subjects: 45

Group type: COMPARATOR
Intervention: PanOptix
Number of subjects: 45
Study: 36303179

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) at a rate of 60 L/min and a concentration of 100% (n = 87)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Facemask at a rate of 6 L/min and a concentration of 100% (n = 89)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Facemask (n = 89)
Number of subjects: 176
Study: 33472722

Group type: EXPERIMENTAL
Intervention: Whole grain intake (half of grain servings from whole grain foods daily for 6 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-intervention (no whole grain foods for 6 weeks)
Number of subjects: 44
Study: 33442853

Group type: COMPARATOR
Intervention: 532-nm Q-switched Nd:YAG laser, 3 sessions at 1-month intervals
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1064-nm low-fluence Q-switched Nd:YAG laser, 6 sessions at 2-week intervals
Number of subjects: 40
Study: 33461756

Group type: EXPERIMENTAL
Intervention: Programmed frozen embryo transfer (n = 357)
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Natural cycle FET (modified natural cycle FET and true natural cycle FET)
Number of subjects: 1136
Study: 32233922

Group type: EXPERIMENTAL
Intervention: Use of the term 'stuttering' during evaluations
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Increased experience with a specific speech-language population
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Knowing a person who stutters
Number of subjects: 141
Study: 34347945

Group type: EXPERIMENTAL
Intervention: Etanercept (n=43)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Adalimumab (n=20)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment (both etanercept and adalimumab)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Transitional B cells
Number of subjects: 63
Study: 33481484

Group type: EXPERIMENTAL
Intervention: CBD oil (150 mg POST, 24 h, 48 h)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (PLC: POST, 24 h, 48 h)
Number of subjects: 13
Study: 33121501

Group type: EXPERIMENTAL
Intervention: BDP/FF/G (100/6/10 µg in TRIMARAN; 200/6/10 µg in TRIGGER)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BDP/FF/G
Number of subjects: 0

Group type: COMPARATOR
Intervention: BDP/FF
Number of subjects: 0
Study: 33377987

Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Number of subjects: 227

Group type: COMPARATOR
Intervention: BAY 94-9027
Number of subjects: 227

Group type: COMPARATOR
Intervention: BAY 94-9027 Q7D
Number of subjects: 227
Study: 33346061

Group type: EXPERIMENTAL
Intervention: Blue covarine containing toothpaste (BCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control toothpaste without pigment (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants' satisfaction with treatment results
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants' evaluation of tooth color
Number of subjects: 0
Study: 32239318

Group type: EXPERIMENTAL
Intervention: 15 polymorphic short tandem repeats (STRs) genetic markers
Number of subjects: 464
Study: 35675081

Group type: EXPERIMENTAL
Intervention: Emergency coronary angiogram (CAG)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Delayed coronary angiogram (CAG)
Number of subjects: 279
Study: 32917424

Group type: EXPERIMENTAL
Intervention: COPE Healthy Lifestyles TEEN Program
Number of subjects: 169
Study: 35924247

Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonavalent HPV vaccine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 20
Study: 34763504

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with cisplatin intracavitary perfusion scheme
Number of subjects: 86

Group type: COMPARATOR
Intervention: Cisplatin intracavitary perfusion scheme
Number of subjects: 86
Study: 32662724

Group type: EXPERIMENTAL
Intervention: Voluntary task selection procedure allowing participants to choose which task to perform on each trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Color selection group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Shape selection group
Number of subjects: 0
Study: 35544384

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) + Lenalidomide (LEN)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) + Valproic Acid (VPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) + Idarubicin (IDA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azacitidine (AZA) alone
Number of subjects: 0
Study: 34144047

Group type: EXPERIMENTAL
Intervention: Vedolizumab IV 300 mg every 8 weeks
Number of subjects: 769
Study: 34044564

Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum at varying pressures (15-16 mmHg)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum at varying pressures
Number of subjects: 424
Study: 32352912

Group type: EXPERIMENTAL
Intervention: Lay health worker intervention (2 educational sessions on HEPA)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Colorectal cancer comparison (2 educational sessions)
Number of subjects: 640
Study: 33573589

Group type: EXPERIMENTAL
Intervention: Journeying through Dementia (JtD) intervention, consisting of both group and individual sessions, with a therapeutic dose of 10 out of 16 sessions.
Number of subjects: 0
Study: 34753085

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 30
Study: 34636734

Group type: EXPERIMENTAL
Intervention: TTP‐Webinar intervention (6-week structured, remote access group intervention)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 196
Study: 34933143

Group type: COMPARATOR
Intervention: taVNS
Number of subjects: 43
Study: 35061237

Group type: EXPERIMENTAL
Intervention: Dietary supplement containing probiotics and botanical extract (group II)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Botanical extracts (group III)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Probiotics (group IV)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (group I)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Dietary supplement (group II)
Number of subjects: 114
Study: 35238144

Group type: COMPARATOR
Intervention: Topical 0.25% w/w finasteride spray (1-4 sprays; 50-200 μl/day) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily finasteride 1 mg oral tablet for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily finasteride 1% topical gel for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily finasteride 1 mg oral tablet for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily finasteride 0.25% topical solution for 7 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical finasteride
Number of subjects: 0
Study: 33917366

Group type: EXPERIMENTAL
Intervention: Breastfeeding Education and Support Intervention (BFESI)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 468
Study: 32365000

Group type: EXPERIMENTAL
Intervention: Repeated Hyperthermia exposure programme (HTC)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Light Intermittent Exercise (LIE) programme
Number of subjects: 34
Study: 34160906

Group type: EXPERIMENTAL
Intervention: Proteomic studies on brain-enriched plasma proteins specific for SCD and silent cerebral infarcts.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unbiased proteomic studies
Number of subjects: 0
Study: 32295716

Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus 0.75 mg/kg followed by an infusion 1.75 mg/kg/h for the duration of the procedure)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Heparin (bolus 70 U/kg)
Number of subjects: 1812
Study: 33462393

Group type: EXPERIMENTAL
Intervention: Mean ABCA1_B methylation
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Mean ABCA1_A methylation in the middle tertile of BMI
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Mean ABCA1_A methylation together with age and gender
Number of subjects: 211
Study: 32418236

Group type: EXPERIMENTAL
Intervention: Occlusal reduction
Number of subjects: 308

Group type: COMPARATOR
Intervention: No occlusal reduction
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 308
Study: 34739584

Group type: EXPERIMENTAL
Intervention: Automated anesthesia control system
Number of subjects: 56

Group type: COMPARATOR
Intervention: Manual anesthesia control by anesthesiologists
Number of subjects: 56

Group type: COMPARATOR
Intervention: Automated anesthesia control system vs Manual anesthesia control
Number of subjects: 56
Study: 33170506

Group type: COMPARATOR
Intervention: Picture Option Grid (n = 248)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Option Grid (n = 66)
Number of subjects: 571
Study: 35778539

Group type: EXPERIMENTAL
Intervention: TBRS training (triweekly for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (NC group)
Number of subjects: 90
Study: 34022462

Group type: EXPERIMENTAL
Intervention: Quantitative computed tomography (QCT) measurements of thoracic spine BMD
Number of subjects: 60
Study: 36209240

Group type: EXPERIMENTAL
Intervention: MoCA Blind/Telephone
Number of subjects: 0

Group type: COMPARATOR
Intervention: In-person MoCA assessment
Number of subjects: 0
Study: 33501810

Group type: EXPERIMENTAL
Intervention: CHB patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy individuals (CN group)
Number of subjects: 25
Study: 34050877

Group type: EXPERIMENTAL
Intervention: Potassium citrate administration
Number of subjects: 65

Group type: COMPARATOR
Intervention: No potassium citrate administration (Control)
Number of subjects: 65
Study: 32616589

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg·day‐1)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 35647191

Group type: EXPERIMENTAL
Intervention: Yoga exercise group (12-week progressive yoga exercise program starting at postpartum week 1)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 116
Study: 33957293

Group type: EXPERIMENTAL
Intervention: CCT-SE (combined compensatory cognitive training and supported employment)
Number of subjects: 116

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 116
Study: 37287522

Group type: EXPERIMENTAL
Intervention: Low-fat plant-based diet
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 244
Study: 34333648

Group type: COMPARATOR
Intervention: 0% SL hay
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 25% SL hay
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 50% SL hay
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 75% SL hay
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100% SL hay
Number of subjects: 25
Study: 32791690

Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention based on rational emotive behaviour therapy (REBT)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 171
Study: 32652863

Group type: EXPERIMENTAL
Intervention: Interval walking training (IT) - 3 sessions of 60 minutes per week for 4 months, with 3-minute intervals of slow and fast walking at 40% and 70% peak energy expenditure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interval walking training (IT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 34978107

Group type: EXPERIMENTAL
Intervention: Underwater endoscopic mucosal resection (UEMR)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional endoscopic mucosal resection (CEMR)
Number of subjects: 210
Study: 33661121

Group type: EXPERIMENTAL
Intervention: Hybrid web-based training program (GET.ON Panic)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 92
Study: 35618377

Group type: EXPERIMENTAL
Intervention: Class norm-framed imagined contact (n=88)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Family norm-framed imagined contact (n=49)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Religious in-group norm-framed imagined contact (n=51)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Standard imagined contact (n=80)
Number of subjects: 269
Study: 34262619

Group type: EXPERIMENTAL
Intervention: Celecoxib + JOINS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib + Placebo
Number of subjects: 0
Study: 33046839

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT) screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LDCT-based screening programmes
Number of subjects: 0
Study: 33884701

Group type: EXPERIMENTAL
Intervention: Inflated dynamic overlay mattress on top of a viscoelastic foam mattress
Number of subjects: 70

Group type: COMPARATOR
Intervention: Viscoelastic foam mattress
Number of subjects: 70
Study: 33837158

Group type: EXPERIMENTAL
Intervention: Interval training with sleep hygiene (SH), n = 6
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sleep hygiene alone, n = 7
Number of subjects: 13
Study: 34968573

Group type: EXPERIMENTAL
Intervention: Robotic paravaginal repair and sacrocolpopexy
Number of subjects: 43
Study: 34658006

Group type: EXPERIMENTAL
Intervention: Sarilumab plus usual care (including corticosteroids at 1 mg/kg/day for at least 3 days)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Usual care alone (including corticosteroids at 1 mg/kg/day for at least 3 days)
Number of subjects: 201
Study: 33070698

Group type: EXPERIMENTAL
Intervention: Resistance exercise session
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (40-minute rest period)
Number of subjects: 23
Study: 33395974

Group type: EXPERIMENTAL
Intervention: rtfMRI neurofeedback (NF) targeting the left lateral prefrontal cortex (lPFC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cognitive reappraisal without feedback (NoNF)
Number of subjects: 41
Study: 35122086

Group type: EXPERIMENTAL
Intervention: Physical Frailty Phenotype (PFP)
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: SHARE-Frailty Instrument (SHARE-FI)
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: SOF-Frailty Index (SOF-FI)
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Country-specific prevalence
Number of subjects: 2144

Group type: EXPERIMENTAL
Intervention: Factors associated with frailty
Number of subjects: 2144
Study: 32239753

Group type: EXPERIMENTAL
Intervention: Swaddling, holding and breastfeeding
Number of subjects: 160

Group type: COMPARATOR
Intervention: Swaddling
Number of subjects: 160

Group type: COMPARATOR
Intervention: Swaddling and holding
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 160
Study: 32815644

Group type: EXPERIMENTAL
Intervention: Healthy Buddies™
Number of subjects: 687

Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Healthy Buddies™ (boys subgroup)
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Healthy Buddies™ (urban subgroup)
Number of subjects: 687
Study: 35557479

Group type: EXPERIMENTAL
Intervention: Pregabalin 50 mg three times a day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketotifen 1 mg twice a day
Number of subjects: 30
Study: 33229940

Group type: EXPERIMENTAL
Intervention: Shenqi DCB
Number of subjects: 216

Group type: COMPARATOR
Intervention: SeQuent Please DCB
Number of subjects: 216
Study: 33380323

Group type: EXPERIMENTAL
Intervention: 45° Trendelenburg position during RALP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (RAPN)
Number of subjects: 80
Study: 35521027

Group type: EXPERIMENTAL
Intervention: Pharmacist education
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 43

Group type: COMPARATOR
Intervention: Text messages
Number of subjects: 43

Group type: COMPARATOR
Intervention: Phone calls
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both interventions (pharmacist and video education)
Number of subjects: 43
Study: 34253208

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with paclitaxel plus cisplatin for two cycles followed by radical hysterectomy and bilateral adnexectomy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Radical hysterectomy and bilateral adnexectomy (control group)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with radical surgery
Number of subjects: 68
Study: 32188988

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (1000 mg/day and 5 mg/day respectively)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 70
Study: 36208817

Group type: EXPERIMENTAL
Intervention: Cigarettes with 0.4 mg nicotine/g tobacco
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Cigarettes with 2.4 mg nicotine/g tobacco
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: Cigarettes with 15.8 mg nicotine/g tobacco
Number of subjects: 753

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 753
Study: 34981483

Group type: EXPERIMENTAL
Intervention: Curcumin (500 mg per 12 hours)
Number of subjects: 80
Study: 37133765

Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy–Bladder Cancer (FACT-BL)
Number of subjects: 100
Study: 32951013

Group type: EXPERIMENTAL
Intervention: Vasopressin infusion at a mean dose of 0.3 ± 0.2 mU/kg/min
Number of subjects: 6
Study: 32460575

Group type: EXPERIMENTAL
Intervention: Symmetry Span Task (working memory)
Number of subjects: 1060

Group type: EXPERIMENTAL
Intervention: Cued Go/No-Go task (response inhibition)
Number of subjects: 1060
Study: 34780705

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine (0.5 mL injection administered on day 1, month 2, and month 6)
Number of subjects: 1803

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1803
Study: 33706033

Group type: EXPERIMENTAL
Intervention: CAM-ICU assessments twice daily for 5 days
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: CAM-ICU assessments twice daily for 4 days
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: CAM-ICU assessments twice daily for 3 days
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Morning assessments
Number of subjects: 788
Study: 33308683

Group type: EXPERIMENTAL
Intervention: Frequently-exercising roommates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-frequently-exercising roommates
Number of subjects: 0
Study: 32654517

Group type: EXPERIMENTAL
Intervention: Histopathologic changes in the right atrial appendage
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: NT-proBNP, hs-cTnT, CRP, oxidative stress biomarkers
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Atrial interstitial fibrosis, cardiomyocyte myocytolysis, cardiomyocyte diameter, glycogen score, Cx43 distribution
Number of subjects: 239